

# Clinical trials of insulin glargine

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>morning insulin glargine vs bedtime insulin glargine</b>			
<b>Fritche</b> n=463/232 follow-up: 24 weeks	morning insulin glargine versus bedtime insulin glargine	patients with type 2 diabetes previously treated with oral antidiabetic agents	open
<b>insulin glargine vs control</b>			
<b>ORIGINE , 2012</b> [NCT00069784] n=6264/6273 follow-up: 6.2 years	insulin glargine (with a target fasting blood glucose level of 95 mg per deciliter versus standard care	with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	
<b>insulin glargine vs placebo</b>			
<b>GRACE - ORIGIN (glargine) , 2012</b> n=1184 follow-up:	insulin glargine (with a target fasting blood glucose level of <=95 mg per deciliter [5.3 mmol per liter]) versus standard glyceimic care alone	subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	Factorial plan open-label
<b>insulin glargine plus insulin glulisine vs premixed insulin analogues</b>			
<b>Levin , 2011</b> n=NA	-	-	

More details and results :

- prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q341>
- prevention for diabetes type 2 in people with impaired glucose tolerance at <http://www.trialresultscenter.org/go-Q416>
- intensive therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q459>
- insulin therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q548>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>

## References

### Fritche , :

Fritsche A, Schweitzer MA, Hring HU Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9 [12809451]

### ORIGINE, 2012:

Gerstein HC, Bosch J, Dagenais GR, Daz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydn LE, Yusuf S Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28 [22686416]

### GRACE - ORIGIN (glargine), 2012:

### Levin, 2011:

Levin PA, Zhang Q, Mersey JH, Lee FY, Bromberger LA, Bhushan M, Bhushan R, Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. Clin Ther 2011;33:841-50. [21719107] 10.1016/j.clinthera.2011.05.091

## 2 impaired fasting glucose

2

Trial	Treatments	Patients	Trials design and methods
<b>insulin glargine vs placebo</b>			
GRACE - ORIGIN (glargine) , 2012 n=1184 follow-up:	insulin glargine (with a target fasting blood glucose level of <=95 mg per deciliter [5.3 mmol per liter]) versus standard glycemic care alone	subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes	Factorial plan open-label

More details and results :

- prevention for impaired fasting glucose in all type of patients at <http://www.trialresultscenter.org/go-Q342>

## References

### GRACE - ORIGIN (glargine), 2012:

Entry terms: glargine